SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (1049)10/23/2001 3:59:46 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 1475
 
Elliot Lebowitz, in passing at the beginning of the presentation, hit on the unique "Belgian" mode of action of 507, and that the mechanism differs at various concentrations.

Elliot re. SCS........ "keep getting these very big pharma contracts", "master gene switch", "vectors and promoters", other comments.

Presentation focused on AlloMune. Only a passing reference to Eligix.